Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid versus risedronate in corticosteroid-induced osteoporosis
2004-000248-25Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of zoledronic acid in osteoporosis (2 arms), sponsored by Novartis. Primary endpoints: Lumbar spine BMD percent change at Month 12 and Lumbar spine, hip and distal radius BMD over time. Started Aug 2004; status: completed.
02
Drugs
zoledronic acid
03
Conditions
osteoporosis
Beyond the preview
Go deeper on 2004-000248-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000248-25.